Advice
In the absence of a submission from the holder of the marketing authorisation
telmisartan (Micardis), is not recommended for use within NHSScotland for use in cardiovascular prevention (to reduce cardiovascular morbidity in patients with manifest atherothrombotic cardiovascular disease history of coronary heart disease, stroke, or peripheral arterial disease) or type 2 diabetes mellitus with documented target organ damage.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice53KB (PDF)
Medicine details
- Medicine name:
- telmisartan (Micardis)
- SMC ID:
- 631/10
- Indication:
- For use in cardiovascular prevention or type 2 diabetes mellitus
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 May 2010